Sun Pharmaceutical Industries Ltd. reported a 2.6% year-on-year rise in net profit to Rs 3,118 crore for the quarter ended September 30, 2025, as strong growth in its innovative medicines portfolio offset weakness in the US generics business.
The net profit rose to Rs 3,118 crore in Q2FY26 from ₹3037.3 crore a year earlier. Revenue climbed 8.6% to Rs 14,405.2 crore, driven by double-digit growth in India, emerging markets, and rest of world (RoW) geographies.
EBITDA grew 14.9% to Rs 4,527.1 crore, with margins expanding to 31.3%. R&D spend stood at Rs 7,827 million, or 5.4% of sales.
"India, Emerging Markets and Rest of World led our growth for the period. US sales of Innovative Medicines have surpassed Generics for the first time during the quarter," said Kirti Ganorkar, Managing Director. "We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability."
India Formulations: Sales rose 11% YoY to ₹4734.8 crore, accounting for 32.9% of total revenue. Sun Pharma retained its No. 1 position in India’s pharma market, with market share rising to 8.3%.
US formulations sales declined 4.1% YoY to $496 million, as generics softened. However, innovative medicines in the US outpaced generics for the first time.
Emerging markets sales grew 10.9% YoY to $325 million, contributing 19.7% to total revenue.
RoW Markets: Sales surged 17.7% YoY to $234 million, accounting for 14.2% of total revenue.
Innovative medicines: sales jumped 16.4% YoY to $333 million, making up 20.2% of total revenue. The company launched Leqselvi in the US for severe alopecia areata, which received encouraging response.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
